June 7, 2008 — New data from a sub-group analysis of patients with mixed dyslipidemia and type 2 diabetes that were enrolled in a Phase III study showed that the use of Abbott's (NYSE: ABT) investigational TriLipix™ (ABT-335) in combination with AstraZeneca's CRESTOR® (rosuvastatin calcium), demonstrated similar improvements in LDL "bad" cholesterol, HDL "good" cholesterol and triglycerides compared to the overall study population. These data were presented at the American Diabetes Association's (ADA) 68th Annual Scientific Sessions in San Francisco. Abbott evaluated the efficacy and safety of TriLipix in combination with rosuvastatin in a Phase III study of more than 1,400 patients with mixed dyslipidemia. This study, presented at the National Lipid Association annual meeting on May 31, 2008, met its primary endpoints. TriLipix in combination with rosuvastatin significantly improved HDL and triglycerides compared to rosuvastatin alone, and significantly improved LDL compared to TriLipix alone.
Of the patients enrolled in this study, a sub-group of 276 patients were identified as having type 2 diabetes... Abbott's Press Release -
